• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Cancer Vaccine Partnering Terms and Agreements (6th Edition) Product Image

Cancer Vaccine Partnering Terms and Agreements (6th Edition)

  • ID: 2074847
  • December 2014
  • Region: Global
  • 294 Pages
  • CurrentPartnering

FEATURED COMPANIES

  • Adamis Pharmaceuticals
  • BioVest
  • Encorium Group
  • Janssen Pharmaceuticals
  • Nottingham City Council
  • San Martino Hospital
  • MORE

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in cancer vaccine partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer vaccine partnering contract documents
Top cancer vaccine deals by value

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Adamis Pharmaceuticals
  • BioVest
  • Encorium Group
  • Janssen Pharmaceuticals
  • Nottingham City Council
  • San Martino Hospital
  • MORE

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cancer vaccine dealmaking

2.1. Introduction
2.2. Cancer vaccine partnering over the years
2.3. Big pharma cancer vaccine dealmaking activity
2.3. Big biotech cancer vaccine dealmaking activity
2.4. Most active in cancer vaccine partnering
2.5. Cancer vaccine partnering by deal type
2.6. Cancer vaccine partnering by stage of development
2.7. Cancer vaccine partnering by cancer indication
2.8. Disclosed deal terms for cancer vaccine partnering
2.8.1 Cancer vaccine partnering headline values
2.8.2 Cancer vaccine deal upfront payments
2.8.3 Cancer vaccine deal milestone payments
2.8.4 Cancer vaccine royalty rates
2.9. The anatomy of cancer vaccine partnering
2.9. The anatomy of a cancer vaccine deal
2.9. a. Case study 1: Stemline Therapeutics, University of Pittsburgh- March 30 2012
2.9. b. Case study 2: Agenus Bio, NewVac: Dec 19, 2011

Chapter 3 - Leading cancer vaccine deals

3.1. Introduction
3.2. Top cancer vaccine deals by value

Chapter 4 - Cancer vaccine dealmaking directory

4.1. Introduction
4.2. Cancer vaccine deals by company A-Z
4.3. Cancer vaccine deals by stage of development
4.4. Cancer vaccine deals by deal type
4.5. Cancer vaccine deals by oncology therapy area
4.6. Cancer deals by vaccines and adjuvant technology

Chapter 5 - Partnering resource center

5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions

Order Form - Upgrades to subscription access products
Order Form - Technology Reports

Table of figures

Figure 1: Cancer vaccine partnering since 2009
Figure 2: Big pharma - top 50 - cancer vaccine deals 2009 to 2014
Figure 3: Big pharma cancer vaccine deal frequency - 2009 to 2014
Figure 4: Big biotech - top 50 - cancer vaccine deals 2009 to 2014
Figure 5: Big biotech cancer vaccine deal frequency - 2009 to 2014
Figure 6: Active cancer vaccine dealmaking activity- 2009 to 2014
Figure 7: Cancer vaccine partnering by deal type since 2009
Figure 8: Cancer vaccine partnering by stage of development since 2009
Figure 9: Cancer vaccine partnering by oncology target since 2009
Figure 10: Cancer vaccine deals with a headline value - by stage of development
Figure 11: Cancer vaccine deal headline value distribution, US$million - discovery stage
Figure 12: Cancer vaccine deal headline value distribution, US$million - preclinical stage
Figure 13: Cancer vaccine deal headline value distribution, US$million - phase I stage
Figure 14: Cancer vaccine deal headline value distribution, US$million - phase II stage
Figure 15: Cancer vaccine deal headline value distribution, US$million - phase III stage
Figure 16: Cancer vaccine deal headline value distribution, US$million - regulatory stage
Figure 17: Cancer vaccine deal headline value distribution, US$million - marketed stage
Figure 18: Cancer vaccine deal headline value - median value by stage of development
Figure 19: Cancer vaccine deals with upfront payment values - by stage of development
Figure 20: Cancer vaccine deal upfront value distribution, US$million - discovery stage
Figure 21: Cancer vaccine deal upfront value distribution, US$million - preclinical stage
Figure 22: Cancer vaccine deal upfront value distribution, US$million - phase I stage
Figure 23: Cancer vaccine deal upfront value distribution, US$million - phase II stage
Figure 24: Cancer vaccine deal upfront value distribution, US$million - phase III stage
Figure 25: Cancer vaccine deal upfront value distribution, US$million - regulatory stage
Figure 26: Cancer vaccine deal upfront value distribution, US$million - marketed stage
Figure 27: Cancer vaccine deal upfront payment value - median value by stage of development
Figure 28: Cancer vaccine deals with milestone payment - by stage of development
Figure 29: Cancer vaccine deal milestone value distribution, US$million - discovery stage
Figure 30: Cancer vaccine deal milestone value distribution, US$million - preclinical stage
Figure 31: Cancer vaccine deal milestone value distribution, US$million - phase I stage
Figure 32: Cancer vaccine deal milestone value distribution, US$million - phase II stage
Figure 33: Cancer vaccine deal milestone value distribution, US$million - phase III stage
Figure 34: Cancer vaccine deal milestone value distribution, US$million - regulatory stage
Figure 35: Cancer vaccine deal milestone value distribution, US$million - marketed stage
Figure 36: Cancer vaccine deals with royalty rates-by stage of development
Figure 37: Cancer vaccine deal royalty rate value distribution, US$million - discovery stage
Figure 38: Cancer vaccine deal royalty rate value distribution, US$million - preclinical stage
Figure 39: Cancer vaccine deal royalty rate value distribution, US$million - phase I stage
Figure 40: Cancer vaccine deal royalty rate value distribution, US$million - phase II stage
Figure 41: Cancer vaccine deal royalty rate value distribution, US$million - phase III stage
Figure 42: Cancer vaccine deal royalty rate value distribution, US$million - regulatory stage
Figure 43: Cancer vaccine deal royalty rate value distribution, US$million - marketed stage
Figure 44: Cancer vaccine deal royalty rate payment value - median value by stage of development
Figure 45: Components of the typical cancer vaccine deal structure
Figure 46: Top cancer vaccine deals by value since 2009
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events
Figure 49: Deal type definitions

Note: Product cover images may vary from those shown

A*STAR Bioprocessing Technology Institute
AV Therapeutics
Adamis Pharmaceuticals
Adjuvantix
AdnaGen
Aduro BioTech
Advaxis
Affitech
Agenus Bio
Agilent Technologies
Aldevron
Alexis Biotech
Alnylam Pharmaceuticals
AnGes MG
Antigen Express
Antigenics
Argos Therapeutics
Ariad Pharmaceuticals
Asterias Biotherapeutics
AstraZeneca
Astrimmune
Averion
Batu Biologics
Bavarian Nordic
Bayer Innovation
Baylor College
Baylor College of Medicine
Baylor Research Institute
Beijing Genomics Institute (BGI)
Bellicum Pharmaceuticals
Beth Israel Deaconess Medical Center
BinnoPharm
Bio-Matrix Scientific
BioAlliance Pharma
BioClones
BioSante Pharmaceuticals
BioTime
BioVest
BioWa
Biooutsource
Bristol-Myers Squibb
Broadvector
Brown University
CSIRO
CSL
Cadila Pharmaceuticals
Cancer Prevention and Research Institute of Texas
Cancer Research Institute
Cancer Research Technology
Cancer Research UK
Cancer Research Wales
Cardiff University
Catherex
Cedars-Sinai Medical Center
Champions Oncology
ChemRar High-Tech Center
City of Hope
Cleveland BioLabs
Clinigen
Clinipace Worldwide
Cobra Biologics
Colby Pharmaceuticals
CureLab Oncology
CureVac
DCPrime
Daiichi Sankyo
Dalton Pharma Services
DanDrit Biotech
Dana-Farber Cancer Institute
Davis
Davospharma
Delta-Vir
Dendreon
Department of Defense
Diosynth
Dynavax Technologies
Encorium Group
Entest BioMedical
Etubics
European Union
Federal Ministry of Education and Research (BMBF)
Formatech
Forska and Vax
Fraunhofer Institute for Cell Therapy and Immunology
Fred Hutchinson Cancer Research Center
G-Con
Galena Biopharma
Genentech
Generex Biotechnology
Genetic Immunity
GenoLac
Genomic Expression
German Cancer Research Center
GlaxoSmithKline
Gradalis
Gynecologic Oncology Group
Heat Biologics
HemaCare
HemispheRx Biopharma
Hokkaido University
IBio
IRX Therapeutics
ISSI-Strategy
Icahn School of Medicine at Mount Sinai
Ichor Medical Systems
Immatics Biotechnologies
Immune Design
ImmuneRegen BioSciences
Immunicum
ImmunoCellular Therapeutics
ImmunoVaccine Technologies
Immunomedics
Immunotope
Immunovaccine
Immunovo
Inovio Pharmaceuticals
InteRNA Technologies
JSC Binnopharm
Jaiva Technologies
Janssen Pharmaceuticals
Jantibody Therapeutics
Japan Vaccine
Jennerex
John Hopkins University School of Medicines
Johns Hopkins University
Juvaris BioTherapeutics
KAEL-GemVax
KellBenx
Kirin Pharma
Kyowa Hakko Kirin
LUNGevity Foundation
Leukaemia & Lymphoma Research
Ligand Pharmaceuticals
Lipoxen
London Genetics
Ludwig Institute for Cancer Research
MD Anderson Cancer Center
MabVax Therapeutics
Madison Vaccines
Mary Crowley Cancer Research Center
Mayo Clinic
MedImmune
Medarex
MediGene
Memorial Sloan Kettering Cancer Center
Merck KGaA
Merck Serono
Merck and Co
Merix Bioscience
Methodist Hospital Research Institute
Ministry of Industry and Trade of the Russian Federation
MorphoSys
Morphotek
NYU Langone Medical Center
Nanobiotix
National Cancer Institute
National Cancer Research Center
National Institute of Allergy and Infectious Diseases
National Institute of Dental and Craniofacial Research (NIDCR)
National Institutes of Health
National Research Council Canada
NeoStem
NewVac
Northwest Biotherapeutics
Norwegian Cancer Society
Norwegian Research Council
Nottingham City Council
Novartis
Novavax
Numoda
Ohio State University
Omnimmune
OncoPep
OncoSec Medical
Oncotherapy Science
Oncothyreon
Oncovir
Ono Pharmaceutical
Opsona Therapeutics
Oxford BioMedica
Oxford Immunotec
PPD
Panacela Labs
Pepscan Therapeutics
Pfenex
Pfizer
Pharmsynthez
Pique Therapeutics
Pro-Cure Therapeutics
Progenitor Cell Therapy
Prometheus Laboratories
Prostate Cancer Foundation (PCF)
PsiOxus Therapeutics
Pulmotec
Qiagen
RXi Pharmaceuticals
Radboud University Nijmegen Medical Centre
Radiation Control Technologies
Radient Pharmaceuticals
Regen BioPharma
Roche
Rosetta Genomics
SFJ Pharmaceuticals
SOTIO
San Diego
San Martino Hospital
Scancell
Sellas Clinicals Holding
Spectrum Pharmaceuticals
Stellar Biotechnologies
Stellar Pharmaceuticals
Stemline Therapeutics
Symphony Dynamo
TapImmune
Tasly Pharmaceuticals
Technomark Life Sciences
Teva Pharmaceutical Industries
The Regents of the University of California
Therinject
ToleRx
Torrey Pines Institute for Molecular Studies
Transgene
Transgene Tasly Biopharmaceutical
UK Government
University of California
University of California
University of Connecticut
University of Copenhagen
University of Miami
University of Pennsylvania
University of Pennsylvania School of Veterinary Medicine
University of Pittsburgh
University of Queensland
University of Rouen
University of Western Ontario
VLST Corporation
VU University Amsterdam
Vaccibody
Vaccinogen
Vanderbilt University
Vaxil BioTherapeutics
Vaximm
Vinnova
ViroMed
Vivalis
Wilex
Wistar Institute
Xencor

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos